Lakefront Biotherapeutics NV (LKFT)
Lakefront Biotherapeutics NV reported revenue of 139.8M EUR for the quarter ending 30 June 2021, up 419.0% from 26.9M a year earlier.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in EUR.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in EUR.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
Q2 '21 · ending 30 June 2021 |
139.8M |
+419.0% |
| Operating Income |
Q2 '21 · ending 30 June 2021 |
-46.8M |
— |
| Net Income |
Q2 '21 · ending 30 June 2021 |
-64.3M |
— |
| EPS |
2025 · ending 31 December 2025 |
4.87 |
+334.8% |
Revenue and profit by financial year
As filed, in EUR. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2025 | 2025-12-31 |
1.1B | 295M | 320.9M | -271.2M |
|---|
| 2024 | 2024-12-31 |
275.6M | -188.3M | 74.1M | -336.7M |
|---|
| 2023 | 2023-12-31 |
239.7M | -88.3M | 211.7M | -424.7M |
|---|
| 2022 | 2022-12-31 |
241.2M | -131.1M | -218M | -527.9M |
|---|
| 2021 | 2021-12-31 |
234.4M | -171.6M | -103.2M | -558M |
|---|
| 2020 | 2020-12-31 |
478.1M | -178.6M | -305.4M | -469.9M |
|---|
| 2019 | 2019-12-31 |
834.9M | 368.7M | 149.8M | 3.2B |
|---|
| 2018 | 2018-12-31 |
278.7M | -47.1M | -29.3M | -152.9M |
|---|
| 2017 | 2017-12-31 |
127.1M | -89.8M | -115.7M | -152.3M |
|---|
| 2016 | 2016-12-31 |
129.5M | -11.5M | 54M | 234.9M |
|---|
Every period
Revenue Quarterly
| Period | Ending | Revenue |
|---|
| Q2 '21 | 2021-06-30 | 139.8M |
|---|
| Q2 '20 | 2020-06-30 | 99.6M |
|---|
| Q2 '19 | 2019-06-30 | 58.7M |
|---|
| Q2 '18 | 2018-06-30 | 49.7M |
|---|
| Q2 '17 | 2017-06-30 | 26.9M |
|---|
Operating Income Quarterly
| Period | Ending | Operating Income |
|---|
| Q2 '21 | 2021-06-30 | -46.8M |
|---|
| Q2 '20 | 2020-06-30 | -88.2M |
|---|
| Q2 '19 | 2019-06-30 | -44.4M |
|---|
| Q2 '18 | 2018-06-30 | -33.8M |
|---|
| Q2 '17 | 2017-06-30 | -21.7M |
|---|
Net Income Quarterly
| Period | Ending | Net Income |
|---|
| Q2 '21 | 2021-06-30 | -64.3M |
|---|
| Q2 '20 | 2020-06-30 | -115M |
|---|
| Q2 '19 | 2019-06-30 | -47.2M |
|---|
| Q2 '18 | 2018-06-30 | -21.8M |
|---|
| Q2 '17 | 2017-06-30 | -35.6M |
|---|
EPS Annual
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
| Period | Ending | EPS |
|---|
| FY25 | 2025-12-31 | 4.87 |
|---|
| FY24 | 2024-12-31 | 1.12 |
|---|
| FY23 | 2023-12-31 | 3.21 |
|---|
| FY22 | 2022-12-31 | -3.32 |
|---|
| FY21 | 2021-12-31 | -1.58 |
|---|